Long-term treatment of 12 children with chronic hypoparathyroidism: A randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 6, 2010, Pages 2680-2688

  Winer, Karen K ^a   Sinaii, Ninet ^a,b   Reynolds, James ^a   Peterson, Donna ^a   Dowdy, Karen ^a   Cutler Jr , Gordon B ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM CARBONATE; CALCIUM ION; COLECALCIFEROL; MAGNESIUM; PARATHYROID HORMONE[1-34]; PHOSPHORUS; CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; PARATHYROID HORMONE; VITAMIN D;

ADOLESCENT; ARTICLE; BODY GROWTH; BONE DENSITY; BONE PAIN; BONE TURNOVER; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG SAFETY; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HYPOCALCEMIA; HYPOPARATHYROIDISM; KIDNEY FUNCTION; LONG TERM CARE; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEIZURE; BIOASSAY; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; GROWTH; HORMONE SUBSTITUTION; KIDNEY FUNCTION TEST; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; BONE DENSITY; CALCITRIOL; CALCIUM; CALCIUM CHANNEL AGONISTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; GROWTH; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOPARATHYROIDISM; KIDNEY FUNCTION TESTS; LONG-TERM CARE; MAGNESIUM; MALE; PARATHYROID HORMONE; PHOSPHORUS; TREATMENT OUTCOME; VITAMIN D; WEIGHT GAIN;

EID: 77954468040     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2464     Document Type: Article

References (15)

1. Weber G, Cazzuffi MA, Frisone F, de Angelis M, Pasolini D, Tomaselli V, Chiumello G 1988-1989 Nephrocalcinosis in children and adolescents: sonographic evaluation during long-term treatment with 1,25-dihydrocholecalciferol. Child Nephrol Urol 9:273-276 (Pubitemid 20071422)
2. Santos F, Smith MJ, Chan JC 1986 Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D). Am J Dis Child 140:139-142
3. Strögmann W, Bohrn E, Woloszezuk W 1990 First experiences in the substitution treatment of hypoparathyroidism with synthetic human parathyroid hormone. Monatsschr Kinderheilkd 138:141-146
4. Winer K, Yanovski JA, Cutler Jr GB 1996 Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism: results of a randomized crossover trial. JAMA 276:631-636 (Pubitemid 26278069)
5. Winer KK, Yanovski JA, Sarani B, Cutler Jr GB 1998 A randomized, crossover trial of once-daily vs twice-daily human parathyroid hormone 1-34 in the treatment of hypoparathyroidism. J Clin Endocrinol Metab 83:3480-3486
6. Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler Jr GB 2003 Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 88:4214-4220
7. Slovik DM, Neer RM, Potts Jr JT 1981 Short-term effects of synthetic humanparathyroidhormone1-34 administrationonbone mineral metabolism in osteoporotic patients. J Clin Invest 68:1261-1271
8. Slovik DM, Rosenthal DI, Doppelt SH, Potts Jr JT, Daly MA, Campbell JA, Neer RM 1986 Restoration of spinal bone in osteoporotic men by treatment with parathyroid hormone 1-34 and 1,25 dihydroxyvitamin D. J Bone Miner Res 1:377-381
9. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM 1994 Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331:1618-1623
10. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone 1-34 on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
11. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-321 (Pubitemid 34556102)
12. Winer KK, Sinaii N, Peterson D, Sainz Jr B, Cutler Jr GB 2008 Effects of once versus twice-daily parathyroid hormone1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab 93:3389-3395
13. Baron J, Winer KK, Yanovski JA, Cunningham AW, Laue L, Zimmerman D, Cutler Jr GB 1996 Mutations in the Ca-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism. Hum Mol Genet 5:601-606 (Pubitemid 126504204)
14. Kuczmarski R, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL 2002 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 246:1-190
15. Kalkwarf HJ, Zemel BS, Gilsanz V, Lappe JM, Horlick M, Oberfield S, Mahboubi S, Fan B, Frederick MM, Winer K, Shepherd JA 2007 The bone mineral density in childhood study (BMDCS): bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab 92:2087-2099